Cargando…
ODP064 Latrogenic Cushing Syndrome after Concomitant Oral Controlled-Release Budesonide and Famotidine Therapy
INTRODUCTION: It has been shown that complement factors are increased in polycystic ovary syndrome (PCOS) and that these may be affected by obesity and insulin resistance. Hypothetically, this may increase cardiometabolic risk but, paradoxically, increased clotting is not a feature of PCOS. To inves...
Autores principales: | Salhah, Hiba, Bowden, Sasigarn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625769/ http://dx.doi.org/10.1210/jendso/bvac150.143 |
Ejemplares similares
-
ODP621 Hypertension with Hypokalemia in Pregnancy? Think "Cushing's Syndrome"
por: Al Tameemi, Mohammed, et al.
Publicado: (2022) -
ODP639 The Occurrence and Predictors of Postoperative Adrenal Insufficiency for Patients With Subclinical Cushing's Syndrome
por: Da-long, Zhu, et al.
Publicado: (2022) -
ODP018 A Case of Cushing's Syndrome due to Primary Bilateral Macronodular Adrenal Hyperplasia
por: Veluru, Manasa, et al.
Publicado: (2022) -
ODP144 Cushing Syndrome and Primary Hyperaldosteronism due to Synchronic Bilateral Adrenal Adenomas with Exclusive Production of Cortisol on the Right and Aldosterone on the Left
por: Rolim, Marina Rocha, et al.
Publicado: (2022) -
PSAT044 Management of Severe Cushing's Syndrome in a Patient with Cyclical Ectopic ACTH Production Treated with Osilodrostat.
por: Obeid, Hiba, et al.
Publicado: (2022)